Healio

Researchers observe no difference between subcutaneous and IV infliximab treatment in IBD

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous infliximab maintained remission among patients with inflammatory bowel disease who ...
Business Wire

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Medscape

Meta-Analysis Favors SubQ Infliximab Biosimilar Over Vedolizumab in Crohn's Disease

An infliximab biosimilar (infliximab-axxq) delivered via subcutaneous injection was superior to intravenous vedolizumab (Entyvio) for induction and maintenance therapy of Crohn's disease (CD), ...
Nasdaq

European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5 Tecentriq SC ...
MedPage Today

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...